Trandolaprilate

C7HJO 100-51-6) see Fluoxetine Gabapentin Ganciclovir Levocabastine Moexipril Nicotinic acid benzyl ester Perindopril Quinapril hydrochloride Ramipril Saquinavir Trandolapril benzylamine... 

C23H30O7 133991-63-6) see Loteprednol etabonate (3p,16p,17a,18p,20a)-18-[[3-I4-t(ethoxycarbonyl)oxy]-3-methoxyphenyl)-l-oxo-2-propenyl]oxy]-ll,17-dimeth-oxyyohimban-16-carboxylic acid methyl ester (C3ftH42N20(o 49806-34-0) see Rescimetol AT-(l-ethoxycarbonyI-3-phenylpropyl)-L-alanine (C,, H 3N04) see Quinapril hydrochloride A7-[l(5)-ethoxycarbonyl-3-phenylpropyl]-L-alanine (C,gH2 N04 82717-962) see Imidapril Moexipril Quinapril hydrochloride Spirapril Trandolapril A -[l(5)-ethoxycarbonyl-3-phenylpropyl]-L-aIanine benzo-thiazol-2-yIthio ester... 

QH7N 120-72-9) see Indalpine Indoramin Tinazoline hydrochloride Trandolapril indole-3-carbonyl chloride (C H ClNO 59496-25-2) see Tropisetron indole-3-carboxylic acid... 

CjiHiyN iO . 9/022-35-0) see Mosapramine (25, 3a/f,7a5)>octahydro-l//-indole-2-carboxylic acid (C9H15NO2 145438-94-4) see Trandolapril (25,3a5 7a5)-octahydroindole-2-carboxylic acid (CyHi,N02 80875-98-5) see Perindopril [2S-(2a,3aa,7aP)]-octahydro-l/f-indole-2-carboxylic acid phenylmethyl ester... 

Trandolapril (Mavik) 1-4 (perindopril) Stroke (perindopril + indapamide)... 

International Verapamil-Trandolapril Study Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study intrinsic sympathomimetic activity intravenous... 

Trandolapril 1 mg initially target dose 4 mg once daily. 

Undesired effects. The magnitude of the antihypertensive effect of ACE inhibitors depends on the functional state of the RAA system. When the latter has been activated by loss of electrolytes and water (resulting from treatment with diuretic drugs), cardiac failure, or renal arterial stenosis, administration of ACE inhibitors may initially cause an excessive fall in blood pressure. In renal arterial stenosis, the RAA system may be needed for maintaining renal function and ACE inhibitors may precipitate renal failure. Dry cough is a fairly frequent side effect, possibly caused by reduced inactivation of kinins in the bronchial mucosa. Rarely, disturbances of taste sensation, exanthema, neutropenia, proteinuria, and angioneurotic edema may occur. In most cases, ACE inhibitors are well tolerated and effective. Newer analogues include lisinopril, perindo-pril, ramipril, quinapril, fosinopril, benazepril, cilazapril, and trandolapril. 

Tirofiban Tizanidine Tobramycin Tocainide Tolbutamide Tolcapone Tolmetin Tolnaftate Tolonium chloride Tolterodine tartrate Topiramate Tramadol Trandolapril Tranexamic acid Tranylcypromine... 

Heart failure post-Mi/ieft-ventricuiar dysfunction post-MI (trandolapril, ramipril) For stable patients who have evidence of left-ventricular systolic dysfunction (identified... 

Initial dose The recommended initial dosage of trandolapril for patients not receiving a diuretic is 1 mg/day (2 mg in black patients). Adjust dosage according to the BP response. Make dosage adjustments at intervals of 1 week or more. Most patients have required dosages of 2 to 4 mg/day. 

Maintenance - Patients inadequately treated with once daily dosing at 4 mg may be treated with twice-daily dosing. If BP is not adequately controlled with trandolapril monotherapy, a diuretic may be added. 

Concomitant diuretic - In patients being treated with a diuretic, symptomatic hypotension can occasionally occur following the initial dose of trandolapril. To reduce the likelihood of hypotension, if possible, discontinue the diuretic 2 to 3 days prior to beginning therapy with trandolapril. If BP is not controlled with trandolapril alone, resume diuretic therapy. If the diuretic cannot be discontinued, give an initial dose of 0.5 mg trandolapril with careful medical supervision for several hours until BP has stabilized. Titrate dosage as described above to the optimal response. 

Neutropenia/Agranulocytosis Neutropenia (less than 1000/mnr ) with myeloid hypoplasia resulted from captopril use. About half of the neutropenic patients developed systemic or oral cavity infections or other features of agranulocytosis. Neutropenia/agranulocytosis has occurred rarely with enalapril or lisinopril and in 1 patient on quinapril. Data are insufficient to show that moexipril, ramipril, quinapril, benazepril, trandolapril, orfosinopril do not cause agranulocytosis at similar rates. Periodically monitor WBC counts. 

Lactation Several AC Els have been detected in breast milk. Do not administer trandolapril or ramipril to nursing mothers. It is not known whether lisinopril, moexipril, or ramipril is excreted in breast milk. Discontinue nursing or the drug. Chiidren Safety and efficacy have not been established. Use captopril in children only when other measures for controlling BP have not been effective. 

Hyperkaiemia Elevated serum potassium (at least 0.5 mEq/L greater than the upper limit of normal) was observed in 0.4% of hypertensive patients given trandolapril, approximately 1% of hypertensive patients given benazepril, enalapril, ramipril, or moexipril approximately 2% of patients receiving quinapril or lisinopril, approximately 2.6% of hypertensive patients given fosinopril, and approximately 4.8% of CHF patients given lisinopril. Hyperkalemia also occurred with captopril. Vaivuiar stenosis Theoretically, patients with aortic stenosis might be at risk of decreased coronary perfusion when treated with vasodilators, because they do not develop as much afterload reduction as others. 

---